Jeppsson A, James S, Moller CH, Malm CJ, Dalén M, Vanky F et al.
N Engl J Med 2025; 393: 2313-2323.
Among 2,201 included patients, rates of death, myocardial infarction, stroke or repeat revascularization at 1-year were similar between groups (hazard ratio 1.06, 95 per cent confidence interval 0.72 to 1.56, P=0.77). However, net adverse event was higher in the ticagrelor-plus-aspirin group (hazard ratio 1.45, 1.07 to 1.97), and major bleeding more common (hazard ratio 2.50, 1.52 to 4.11).
Comment: Addition of ticagrelor to aspirin after CABG – no benefit, more harm.
.png)
.jpg){kind=logo}
